Bedel Financial Consulting, Inc. - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 213 filers reported holding DENALI THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.25 and the average weighting 0.4%.

Quarter-by-quarter ownership
Bedel Financial Consulting, Inc. ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q4 2021$7,000
-12.5%
1540.0%0.00%
-33.3%
Q3 2021$8,000
-33.3%
1540.0%0.00%
-25.0%
Q2 2021$12,000
+33.3%
1540.0%0.00%
+33.3%
Q1 2021$9,000
-30.8%
1540.0%0.00%
-50.0%
Q4 2020$13,000
+116.7%
1540.0%0.01%
+100.0%
Q3 2020$6,000
+50.0%
1540.0%0.00%
+50.0%
Q2 2020$4,000
+33.3%
1540.0%0.00%0.0%
Q1 2020$3,0000.0%1540.0%0.00%0.0%
Q4 2019$3,000
+50.0%
1540.0%0.00%
+100.0%
Q3 2019$2,0001540.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q2 2021
NameSharesValueWeighting ↓
Crestline Management, LP 7,460,732$240,012,00028.78%
Casdin Capital, LLC 1,500,000$48,255,0002.16%
Flagship Pioneering Inc. 2,619,968$84,284,0001.98%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 38,000$8,192,0001.85%
Yiheng Capital Management, L.P. 1,014,684$32,642,0001.49%
SECTORAL ASSET MANAGEMENT INC 207,100$6,662,0001.18%
Artal Group S.A. 600,000$19,302,0000.81%
GILDER GAGNON HOWE & CO LLC 2,619,217$84,260,0000.78%
Temasek Holdings (Private) Ltd 5,369,487$172,736,3970.73%
BRANDYWINE MANAGERS, LLC 9,601$309,0000.53%
View complete list of DENALI THERAPEUTICS INC shareholders